ACTR-71. FULL ENROLLMENT RESULTS FROM THE PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) ± BEVACIZUMAB (BEV) IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, RGBM)

MRZ – an irreversible, brain-penetrant, pan-proteasome inhibitor with anti-glioma preclinical activity – was evaluated in BEV-naïve rGBM patients. METHODS: Phase 1 (P1) MRZ+BEV, 3 + 3 MRZ dose-escalation (N=6, 3, 3 at 0.55, 0.7, 0.8 mg/m2) followed by dose-expansion (N=24, 0.8 mg/m2). Phase 2 (P2) M...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Bota, Daniela, Desjardins, Annick, Mason, Warren, Kesari, Santosh, Magge, Rajiv, Winograd, Benjamin, Reich, Steven D, Levin, Nancy, Trikha, Mohit
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692293/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.058
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados